AGG Talks: Healthcare Insights Podcast - Episode 2: Substance Use Disorder Litigation
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 179: Obesity Effects on the Workforce & Economy with Tim Dall, Healthcare Economist
The Presumption of Innocence Podcast: Episode 29 - A Global Perspective on the Economic Responses to COVID-19
Podcast: Telehealth Post-Public Health Emergency – What to Expect in 2024 – Diagnosing Health Care
Meeting Cancer Reporting Requirements
Changing Telehealth Rules
Taking the Pulse: A Health Care and Life Sciences Video Podcast - Ep. 111 with Will Britt, Chief Counsel for Public Health, SC DHEC
USDA FSIS Proposes to Declare Salmonella an Adulterant in Breaded Stuffed Raw Chicken Products
PFAS Regulatory Update: EPA Issues Updated Drinking Water Health Advisories
Where Do We Stand on COVID-19? A Conversation with Andy Slavitt
Rob DeConti on the Latest Guidance and Insights from the OIG at HHS
#WorkforceWednesday: Evolving Pandemic Regulations, Overtime Rule Under Review, ACA Upheld - Employment Law This Week®
#WorkforceWednesday: States Adjust COVID-19 Regulations and OSHA ETS Released - Employment Law This Week®
Forever Chemicals: What They are and What is being Done to Minimize Their Impact
The CDC's Guidance for Fully Vaccinated People
What Can Businesses Do After Texas Lifts the Mask Mandate?
COVID-19 Vaccines: The Ethical and Legal Challenges to Immunization
The Responsible Corporate Officer Doctrine and the Food, Beverage and Agribusiness Industry — What You Need to Know
Chicago Mayor Lori Lightfoot on Policing Reform
#WorkforceWednesday: CDC Permits Shortened Quarantine Periods, CAL/OSHA COVID-19 Regulations, NY Amends WARN Act - Employment Law This Week®
Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies,...more
Continuing progress on the initiatives announced in its Biosimilars Action Plan in July 2018, the Food and Drug Administration (FDA) released information about several important biosimilar-related actions on February 3, 2020....more
Nearly 30 years ago, the first law authorizing the Food and Drug Administration (FDA) to collect fees from drug manufacturers to expedite the review of new prescription drug applications was enacted. Since then, additional...more
On 19 February 2019 the U.S. Food and Drug Administration (FDA or the agency) released a draft guidance entitled, "Nonbinding Feedback After Certain FDA Inspections of Device Establishments" (draft guidance) for comment. ...more
The United Kingdom’s National Health Service (NHS) recently announced that in its last fiscal year, it had saved $419 million in switching to biosimilar and generic versions of ten expensive drugs. These savings exceeded the...more